• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    J&J`s Imaavy Comes up Short in Rheumatoid Arthritis Study

    FIERCE PHARMA

    J&J Drops Development of Arthritis Drug After Trial Setback

    REUTERS

    J&J Boosts US Manufacturing Commitment by $2B Amid Tariff Threats

    BIOSPACE

    AZ, Genentech, Merck top oncology HCP promotions: report

    FIERCE PHARMA

    Johnson & Johnson Joins Morgan Stanley`s 23rd Global Conference

    BUSINESSWIRE

    J&J and Legend Launch First Carvykti TV Ad for Multiple Myeloma

    FIERCE PHARMA

    Boston Jury Awards $42M In Johnson Baby Powder Asbestos Case

    BUSINESSWIRE

    J&J files with U.S. FDA to include new evidence in TREMFYA

    PR NEWSWIRE

    Johnson & Johnson to Participate in 2025 Wells Fargo Health Conf

    BUSINESSWIRE

    EU Okays IMBRUVICA for Untreated Mantle Cell Lymphoma

    GLOBENEWSWIRE

    EU Clears DARZALEX for High-Risk Multiple Myeloma Treatment

    GLOBENEWSWIRE

    EU Approves DARZALEX Faspro® for Multiple Myeloma

    PR NEWSWIRE

    Pacira Bio Expands Zilretta Promotion via Strategic Collaboration

    GLOBENEWSWIRE

    J&J Pursues 1st FDA Approval for Icotrokinra in Plaque Psoriasis

    PR NEWSWIRE

    J&J Gets FDA Priority Review For TAR-200 In High-Risk Cancer

    PR NEWSWIRE

    Johnson & Johnson Raises 2025 Outlook After Q2 Results

    BUSINESSWIRE

    Johnson & Johnson Declares Q3 2025 Quarterly Dividend

    BUSINESSWIRE

    Real Chemistry Appoints Three to Catalyze Change

    FIERCE PHARMA

    J&J Records High Innovative Drug Sales Amid Stelara`s Fall

    FIERCE PHARMA

    J&J Raises Outlook Due to Increased Cardiac Device Sales

    FIERCE BIOTECH

    Caplyta`s Fda Application Shows Schizophrenia Relapse Prevention

    PR NEWSWIRE

    J&J Defeats Generic Drugmakers in Appeal Over Schizophrenia Drug

    REUTERS

    J&J seeks EMA approval to expand Akeega

    GLOBENEWSWIRE

    Janssen’s Biologics Stelara Receives Suppl Approval in US

    FDA

    Nipocalimab better than FcRn blockers for gMG in 24-week study

    GLOBENEWSWIRE

    J&J launches AI surgery funding competition with Nvidia, AWS

    FIERCE BIOTECH

    US Babies Lack Key Gut Bacteria Raising Chronic Disease Risk

    GLOBENEWSWIRE

    Nipocalimab Outperforms FcRn Blockers in gMG ITC Study

    GLOBENEWSWIRE

    Imaavy (nipocalimab-aahu) outperforms FcRn blockers in gMG

    PR NEWSWIRE

    CHMP Backs Darzalex for High-Risk Smouldering Myeloma

    GLOBENEWSWIRE

    IMBRUVICA® (ibrutinib) gets CHMP nod for MCL treatment

    GLOBENEWSWIRE

    Talvey and Tecvayli Combo Effective in Multiple Myeloma Patients

    PR NEWSWIRE

    J&J Lymphoma CAR-T hits 100% ORR in 10 patients

    FIERCE BIOTECH

    Clyra Medical Technologies Names Chris Lyon Chief Revenue Officer

    ACCESSWIRE

    IMBRUVICA Combo Shows Edge Over Acalabrutinib in CLL

    GLOBENEWSWIRE

    Tremfya® Inhibits Joint Damage in Psoriatic Arthritis

    PR NEWSWIRE

    Johnson & Johnson Elects Daniel Pinto to Board

    BUSINESSWIRE

    J&J’s Akeega First PARP Combo to Improve HRR-Mutated mHSPC

    GLOBENEWSWIRE

    CARVYKTI® delivers lasting remissions in multiple myeloma

    GLOBENEWSWIRE

    J&J PARP Path Unclear in Prostate Cancer

    FIERCE PHARMA

    ASCO: J&J captures `Breathtaking Moments` at Chicago skyscraper

    FIERCE PHARMA

    Darzalex Subcutaneous Regimen Benefits Newly Diagnosed Myeloma

    GLOBENEWSWIRE

    J&J’s PARP inhibitors Combo Shows Benefit in HRR+ mCSPC

    PR NEWSWIRE

    Johnson & Johnson`s Trispecific Antibody Shows Promise in Myeloma

    PR NEWSWIRE

    Carvykti Infusion Leads to Lasting Remissions in Myeloma

    PR NEWSWIRE

    J&J shares survival data on KLK2 bispecific in prostate cancer

    FIERCE BIOTECH

    J&J Show Early Anti-Tumor Effect Of Pasritamig In Prostate Cancer

    PR NEWSWIRE

    Johnson & Johnson Investor Call on Q2 Results

    BUSINESSWIRE

    FDA Advisors Back Darzalex as Treatment for Early Myeloma

    FIERCE PHARMA

    Johnson & Johnson at Bernstein`s 41st Annual Conference

    BUSINESSWIRE

    FDA Panel Backs Darzalex Faspro for High-Risk Myeloma

    PR NEWSWIRE

    J&J trials IVL-first Strategy in Women with Blocked coronaries

    FIERCE BIOTECH

    J&J, Pfizer and Roche face FDA questions over data applicability

    FIERCE PHARMA

    Johnson & Johnson at Goldman Sachs 46th Annual Health Conference

    BUSINESSWIRE

    Stylus outlines next-gen gene editing mission with $85M in hand

    FIERCE BIOTECH

    Icotrokinra shows skin clearance in scalp and genital psoriasis

    PR NEWSWIRE

    Johnson & Johnson Boosts Global Support for Nursing workforce

    BUSINESSWIRE

    EU Commission Approved Tremfya for Crohn`s disease in adults

    GLOBENEWSWIRE

    J&J gene therapy fails ph. 3 rare eye disease trial

    FIERCE BIOTECH

    Tremfya is first Drug for subcutaneous induced Ulcerative Colitis

    PR NEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.